Evotec SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVOTF research report →
About the company
Evotec SE serves as a prominent global partner, offering comprehensive drug discovery and development services to both the pharmaceutical and biotechnology sectors worldwide. The company is actively involved in advancing pharmaceutical products across a diverse array of therapeutic areas. These encompass, among others, diabetes and its related complications, fibrosis, infectious diseases, central nervous system (CNS) disorders, oncology, pain and inflammatory conditions, immunology, rare diseases, respiratory ailments, and women's health.
- CEO
- Christian Wojczewski
- IPO
- 2009
- Employees
- 4,766
- HQ
- Hamburg, DE
Price Chart
- Market Cap
- $1.19B
- P/E
- -4.73
- P/S
- 1.23
- P/B
- 1.30
- EV/EBITDA
- -23.64
- Div Yield
- 0.00%
- Gross Margin
- 11.47%
- Op Margin
- -13.88%
- Net Margin
- -26.02%
- ROE
- -24.55%
- ROIC
- -7.93%
- Revenue
- $788.08M · -1.12%
- Net Income
- $-103,478,228 · 47.23%
- EPS
- $-0.58 · 47.75%
- Op Income
- $-140,819,237
- FCF YoY
- 28.13%
- 52W High
- $8.58
- 52W Low
- $4.72
- 50D MA
- $6.46
- 200D MA
- $7.13
- Beta
- 1.31
- Avg Volume
- 3
Get TickerSpark's AI analysis on EVOTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our EVOTF coverage
Recent articles, reports, and earnings notes.
No research on EVOTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EVOTF report →Similar companies
Peers in the same neighborhood.